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Abstract: The gastric pathogen and carcinogen Helicobacter pylori (H. pylori) encodes a type
IV secretion system for translocation of the effector protein CagA into host cells. Injected
CagA becomes tyrosine-phosphorylated at the five amino acid residue Glutamate-Proline-
Isoleucine-Tyrosine-Alanine (EPIYA)-sequence motifs. These phosphorylated EPIYA-sites represent
recognition motifs for binding of multiple host factors, which then manipulate signaling pathways to
trigger gastric disease. Thus, efficient detection of single phosphorylated EPIYA-motifs in CagA is
required. Detection of phospho-CagA is primarily performed using commercial pan-phosphotyrosine
antibodies. However, those antibodies were originally generated to recognize many phosphotyrosines
in various mammalian proteins and are not optimized for use in bacteria. To address this important
limitation, we synthesized 11-mer phospho- and non-phospho-peptides from EPIYA-motifs A, B,
and C, and produced three phospho-specific and three non-phospho-specific rabbit polyclonal
CagA antibodies. These antibodies specifically recognized the corresponding phosphorylated
and non-phosphorylated EPIYA-motifs, while the EPIYA-C antibodies also recognized the related
East-Asian EPIYA-D motif. Otherwise, no cross-reactivity of the antibodies among EPIYAs
was observed. Western blotting demonstrated that each EPIYA-motif can be predominantly
phosphorylated during H. pylori infection. This represents the first complete set of phospho-specific
antibodies for an effector protein in bacteria, providing useful tools to gather information for the
categorization of CagA phosphorylation, cancer signaling, and gastric disease progression.
Keywords: CagA; cagPAI; dotblot; EPIYA motifs; Helicobacter pylori; signaling; type IV secretion; Abl
and Src tyrosine kinases
1. Introduction
The Gram-negative pathogen Helicobacter pylori (H. pylori) represents one of the most prevalent
persistent bacterial infections in humans, affecting about half of the world population. The pathogen
is associated with various gastric diseases, such as peptic ulceration, and represents the main risk
factor for the development of gastric cancer [1–4]. A major disease-associated virulence factor is
its type IV secretion system (T4SS) encoded by the cytotoxin-associated genes (cag) pathogenicity
island (cagPAI). The cagPAI is present in the chromosome of highly virulent H. pylori strains but
absent in less virulent isolates. This T4SS represents a syringe-like pilus device positioned in the
bacterial membrane, and pilus formation is induced by contact with the host target cell [5,6]. The only
known effector protein delivered by the cagT4SS to date is CagA [7–9]. CagA is about 125–145 kDa
in size and shares no homology with any other protein in sequence databases. Remarkably, CagA
seems to mimic a host protein [10] that hijacks the tyrosine phosphorylation machinery of the host
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cell [11]. Upon injection by the T4SS, CagA was shown to undergo tyrosine phosphorylation by
Src [12,13] and Abl tyrosine kinases [14–16]. Subsequently, phosphorylated CagA (CagAPY) can bind a
selection of cellular interaction partners with Src homology 2 (SH2) domains to manipulate host cell
signaling. Currently, about 25 cellular binding partners have been identified that can interact with
CagA in a phosphorylation-dependent or phosphorylation-independent manner, manipulating signal
transduction pathways involved in cytoskeletal rearrangements, cell proliferation, cell motility, cell
death, and inflammation to trigger gastric disease, including gastric cancer [17]. Due to these functions,
CagA has been called the first bacterial oncoprotein that acts in mammalian cells [2].
The phosphorylation sites in CagA were identified by site-directed mutagenesis as the so-called
EPIYA (Glu-Pro-Ile-Tyr-Ala)-motifs [13,18–20]. In H. pylori isolates from North America, Europe,
Australia, and some Asian states (e.g., India and Malaysia), three different EPIYA-motifs have been
classified as EPIYA-A, -B, and -C, depending on the neighboring sequence [2,7,21,22]. In isolates
originating from East Asia (e.g., China, Korea and Japan), the EPIYA-C can be replaced by a related
EPIYA-D site. Notable variability in the number and configuration of the EPIYA-sites has been observed
in CagA proteins worldwide [2,16,21–33]. The importance of CagA phosphorylation for the bacteria
is unknown; however, production of CagAPY is required for the characteristic, so-called “scattering”
or “elongation” phenotype, observed for H. pylori-infected cultured gastric epithelial cells, such as
AGS (gastric adenocarcinoma) cells [13,18,34,35]. It was proposed that this phenotype has a key effect
on H. pylori pathogenesis because it may impact various processes, such as wound healing, invasive
growth, or metastasis of cancer cells, as well as immune responses in vivo [36–38].
Observations that CagA undergoes phosphorylation at tyrosine residues upon delivery into host
cells have been mainly monitored by Western blotting and with commercial pan-phosphotyrosine
antibodies [34,39–42]. These antibodies were developed to recognize multiple phosphotyrosine
residues in mammalian cells, but were not specifically raised against bacterial proteins. Our recent
studies identified six of those pan-phosphotyrosine antibodies, most notably PY-20, PY-99, and
PY-100, recognizing both host cell proteins and phospho-CagA [43,44]. Using synthetic phospho-
and non-phospho-peptides derived from each CagA EPIYA-motif, we have shown that a total
of 9–11 amino acids containing the phospho-tyrosine residue in the EPIYA-motifs are necessary
and sufficient for specific detection by these commercial antibodies, but the work revealed vast
variability in sequence recognition [43,44]. In Western-type CagAs, three of the above antibodies
recognized peptides of phosphorylated EPIYA-motifs A, B, and C equally well in vitro, whereas
preferential binding to phosphorylated motif A, and motifs A and C, was found with two and one
other antibodies, respectively [43,44]. However, systematic studies as to whether specific CagA
EPIYA-sites can be detected by these antibodies during infection with H. pylori are not yet available,
and based on the mentioned cross-reactivity might produce ambiguous results. Thus, the generation
of phospho-specific antibodies for single EPIYA-motifs is urgently required. In the past, the generation
of three respective rabbit antibodies was reported, which were produced against the peptide-based
antigens RSVSPEPIpYATIDDL (EPIYA-motif C) [45], VGLSASPEPIpYAT (EPIYA-motif C) [5], and
PEEPIpYTQVAK (EPIYA-motif B) [46]. However, these antibodies were not characterized in detail and
a full set of phospho-specific EPIYA antibodies is not yet available. Here, we report the successful
production of phospho-specific and non-phospho-specific polyclonal CagA antibodies raised against
Western-type EPIYA-motifs A, B, and C, respectively, using 11-mer peptides as antigens. We confirmed
the specificity of each antibody by Western blotting and demonstrate that the set of EPIYA-C antibodies
also recognized the closely related EPIYA-D site. Subsequently, we performed infection experiments
with Western- and East Asian-type H. pylori to study the patterns of CagAPY following delivery into
host cells. These data demonstrate for the first time that each of the CagA EPIYA-motifs can be
phosphorylated upon infection. Our results are, therefore, highly valuable for detailed analysis of
CagA phosphorylation events during infection and for determining their importance in signaling and
gastric disease development by H. pylori.
Cancers 2019, 11, 1163 3 of 17
2. Results
2.1. Phylogenetic Analysis of H. pylori CagA Carrying EPIYA-Motifs A, B, C and D
Currently, various major H. pylori populations have been described in tight relation with humans
in Africa, Asia, Europe, and Sahul [47]. Many of the CagA proteins from these isolates contain the
three EPIYA-sites A, B, and C/D. As a first step, the phylogeny of CagA-ABC/D types from 5 continents
was investigated. The obtained tree separated protein sequences into two clusters: ABD and ABC
(Figure 1). The ABD cluster is divided into Clades I and II, which are composed exclusively of hpEAsia
strains. The ABC cluster is further divided into Clade III, which is composed of hpEurope strains,
Clade IV, which contains strains from hpAsia2, Clade V, which is formed by hpEurope strains, Clade
VI, which is composed of Latin-American strains closely related to the hpEurope population, and
Clade VII, which contains the hpAfrica1 strains. The alignment shown in Figure 2 illustrates that CagA
is characterized by a highly conserved set of amino acids located before and after each of the individual
EPIYA-motifs A, B, and C/D (Figure 2; numbers 1 and 2 at the top of the aligned EPIYA-C/D block).
Figure 1. Neighbor-Joining tree of 29 non-redundant CagA protein sequences of patients from all
continents. The strain names are indicated with the corresponding country when this information
was available. Seven major clusters are identified and labelled with I to VII. Blue dots represent
bootstrap values, the larger dots correspond to 100% and the smaller to 50%, respectively. The grayscale
depicts ABD and ABC sequence types. The CagA protein sequences were downloaded from GenBank
(Supplementary Table S1). For more information see text.
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Figure 2. Sequence alignment of the EPIYA-motifs in CagA proteins from worldwide clinical H. pylori
strains. Schematic representation of the CagA protein (top) and multiple alignment of a relevant segment
(bottom) with color-shaded EPIYA-repeats A, B, and C/D. Variations in their flanking regions were found
among clinical H. pylori isolates from different continents, as indicated above the alignment. The CagA
protein sequences were downloaded from GenBank (Supplementary Table S1) and sequence alignment
was done using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). For more information see text.
2.2. Generation of Phosphorylation-Specific Antibodies against EPIYA-Motifs A, B, and C
In order to perform a systematic study to investigate the phosphorylation states of CagA, we
raised specific antibodies. For this, we synthesized phosphorylated and non-phosphorylated peptides
of each EPIYA-site of the model strain 26695. The peptides were designed so that the tyrosine residue
that could be phosphorylated was positioned in the middle, flanked by five amino acids on both
sides. This resulted in peptides C-STEPIYAKVNK (for EPIYA-A), C-PEEPIYTQVAK (for EPIYA-B), and
C-SPEPIYATIDD (for EPIYA-C). A peptide length of 11 amino acids was chosen because peptides of
this length are able to generate pan-phosphotyrosine antibodies during immunization, while shorter or
longer peptides can result in loss of antibody specificity [48–51]. The peptides were coupled to a carrier
protein, Limulus polyphemus haemocyanin (LPH), via an added amino-terminal cysteine residue, and this
was used to immunize rabbits, employing two animals per peptide. To select for antibodies specifically
recognizing the phosphorylation state of the antigen, all antisera were subjected to immunoglobulin G
(IgG) purification columns coupled with the opposing peptide. After this selective removal step, the
resulting antibodies were tested for their specificity by dotblots carrying each EPIYA-peptide. As the
11-mer EPIYA-motif C sequence is almost identical to that of EPIYA-motif D (C-SPEPIYATIDF), we
also spotted the corresponding EPIYA-D peptides on the dotblots as control. The pan-phosphotyrosine
antibody PY-99 was used as a control, as this recognizes all four phosphorylated EPIYA motifs (Figure 3).
As shown, the obtained IgG antibodies were not only specific for the EPIYA-A, -B, or -C sequences
to which the animals had been immunized, but also for the specific phosphorylation state of these
epitopes (Figure 3). The only exception was noted with the antibodies against EPIYA-motif C, which
also recognized the closely related EPIYA-D peptides. Thus, the produced antibodies had a strong
differentiating specificity for the EPIYA-motifs A, B, and C/D of CagA, and could specifically determine
their phosphotyrosine state.
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Figure 3. Specific recognition of synthetic 11-mer phospho- and non-phospho-peptides derived
from the CagA EPIYA-sites A, B, C, and D by tailor-made antibodies. The indicated phospho- and
non-phospho-peptides of the EPIYA-sites were synthesized and blotted onto Immobilon-P membranes
using a dotblot system. The peptide sequences cover motifs representing phosphorylation sites, which
can be phosphorylated by Src and Abl tyrosine kinases upon infection with H. pylori. Membranes with
the indicated peptides were probed with the six antibodies generated in this study. Three independent
experiments were performed with similar results.
2.3. Monitoring of Phosphorylated EPIYA-Motifs in Multiple Strains Upon Infection of AGS Cells
The raised antibodies were used to confirm that they could be used to study the phosphorylation
patterns of CagAPY proteins during in vitro infection with H. pylori. For this purpose, seven
representative strains carrying the EPIYA A, B, or C-type CagA obtained from patients from different
geographic regions were used to infect AGS cells. The elongation phenotype of the infected cells was
examined over a time course to indicate successful CagA delivery [52–54]. After six h, approximately
55–70% of infected AGS cells exhibited the elongation phenotype, with every individual H. pylori
strain tested, indicating that large quantities of CagAPY were generated at this time point (Figure 4).
The infected cells with attached bacteria were harvested, lysed, and subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blots that were first stained with
the pan-phosphotyrosine antibody PY-99 as a positive control (Figure 5A). The different CagA variants
revealed slightly different band sizes between 130 and 140 kDa, which is in agreement with the variable
amino acid sequences of the encoded proteins (Supplementary Table S1). As expected, the control
antibody recognized various bands of tyrosine-phosphorylated host cell proteins at approximately
45, 60, 80, 125, and 170 kDa (see full-size blots in Supplementary Figure S1, asterisks). Exposure of
the membranes with a commercial α-CagA antibody confirmed that similar amounts of CagA were
loaded in each lane (Figure 5B, top). The other generated non-phospho CagA antibodies also produced
reasonable CagA patterns (Figure 5B, see full-size blots in Supplementary Figure S2). The blots were
then probed with the three α-phospho EPIYA antibodies, respectively. This resulted in strong bands
for phospho-CagA in all seven strains, with very little background signals (Figure 5A). This provides
evidence that detectable amounts of individually phosphorylated EPIYA-motifs A, B, and C were
present. As a negative control, infection using an isogenic T4SS-deficient Sat464∆cagL knockout mutant
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was included, which was unable to translocate CagA; this control produced no phospho-signals for
CagA (Figure 5A, last lanes), further confirming the specificity of our assays. The obtained signals
in the blots were quantitated densitometrically as band intensities and these data are shown in
Supplementary Figure S3. The data are expressed as relative intensity with respect to the strongest
signal in each panel. As expected, this analysis revealed that the relative quantities of bands obtained
for the phospho- and non-phospho CagA variants varied among the strains. The quantification based
on the two commercial antibodies did not coincide with that of our EPIYA-specific antibodies. For most
of the tested strains, one of the EPIYA-motifs was more strongly detected in the phosphorylated
form, while another motif was more dominant in its non-phosphorylated form, but which of the
motifs was predominately phosphorylated varied per strain. Despite this considerable variation
between strains, as an overall trend we detected stronger EPIYA-C signal intensities compared to the
other two variants, independent of their phosphorylation state. Moreover, in most strains the signal
for the non-phosphorylated EPIYA-C motif in CagA proteins was stronger than its phosphorylated
counterpart. This does not necessarily mean that EPIYA-C was more abundant in the phosphorylated
compared to the non-phosphorylated form, as it is possible that the EPIYA-C sequence exhibits a
higher immunogenicity potential compared to the other EPIYAs, resulting in stronger antibody signals.
Since binding efficiency of the antibodies can be also affected by amino acid differences flanking the
EPIYA-motif or even by variable positions in other locations of the protein, differences seen between
strains or between antibodies have to be interpreted with caution.
Figure 4. Different clinical H. pylori strains induce AGS cell elongation during infection. The indicated
ABC-type CagA H. pylori strains were used to infect AGS cells for 6 h. (A) Quantification of elongated
cells was performed in triplicate. Mean values are shown with standard error. (B) Phase contrast
microscopy of AGS cells infected with some representative strains is shown.
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Figure 5. Phosphorylation of CagA EPIYA-motifs during H. pylori infection was investigated using
specific α-phosphotyrosine antibodies. AGS cells were infected for 6 h with CagA-expressing H. pylori
strains from countries of five continents as indicated. The samples in Figure 3 were collected
after photographing and phenotype quantification. Phosphorylation of CagA was examined using
the indicated (A) phospho-specific and (B) non-phospho-specific EPIYA antibodies with α-PY-99
(Santa Cruz) antibodies as control. Loading of equal amounts of CagA in each sample has been
approved by a commercial α-CagA antibody (Austral Biologicals). The phospho-CagA bands of
different sizes (arrows) as well as a set of tyrosine-phosphorylated host cell proteins (asterisk) are
marked. Three independent experiments were performed with similar results. The corresponding
uncropped files are shown in Supplementary Figures S1 and S2, respectively, and the statistics are
shown in Supplementary Figure S3.
2.4. Phosphorylation of EPIYA-Motifs in ABC vs. ABD H. Pylori Strains during an Infection Time Course
Finally, we aimed to study if injected CagA is differentially phosphorylated at certain EPIYA-motifs
during a time course of infection. We directly compared H. pylori carrying the EPIYA-motif ABC with
ABD. For this purpose, we infected AGS cells with the ABC strain 7.13 and ABD strain TN2-GF4-for
45 min up to 9 h (Figure 6). Microscopic monitoring of the infected cells revealed gradually increasing
numbers of elongated cells over time, suggesting proper CagA translocation (Figure 6A,B). Accordingly,
Western blots stained with the three α-phospho EPIYA antibodies showed increasing intensities
for phospho-CagA bands over time for all EPIYAs in both strains (Figure 6C,D). Most notably, the
α-phospho EPIYA-C antibody recognized both the phospho-EPIYA-C site in strain 7.13 and the
phospho-EPIYA-D site in strain TN2-GF4, which were already detectable as visible bands after 45 min
of infection. There were marked differences in band intensities at different time points with the various
other antibodies: signals for the phospho-EPIYA-A and -B sites appeared at a later time point than
EPIYA-C and became visible only after 90 min, subsequently increasing. Objective quantification of
the band intensities of all phospho blots by densitometry confirmed these observations (Figure 6E,F).
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Figure 6. Time-dependent phosphorylation patterns of EPIYA-motifs in H. pylori strains during
infection of AGS cells. The ABC-type CagA H. pylori strain 7.13 (A) and ABD-type CagA H. pylori
strain TN2-GF4 (B) were used to infect AGS cells for the indicated times. Quantification of elongated
cells was performed in triplicate. Mean values are shown with standard error. (C,D) Western blotting
was performed using the three indicated α-phospho EPIYA antibodies with α-CagA and α-β-Actin
as loading controls. (E,F) Quantification of phospho-CagA band intensities in the above blots was
performed in triplicate by densitometry. Mean values are shown with standard error.
3. Discussion
The T4SS effector protein CagA and its EPIYA-motifs represent crucial virulence determinants of
the gastric pathogen H. pylori [2,7,21]. CagA is the first translocated effector protein in the bacterial
kingdom for which a host cell kinase was identified [12,13]. The EPIYA-sites in CagA generally share
the small amino acid alanine at the +1 position and an isoleucine at the −1 position, similar to the
phosphorylation consensus motif EEIYG/E of Src family kinases [12]. In fact, it was demonstrated that Src
as well as Abl tyrosine kinases mediate EPIYA phosphorylation both in vivo and in vitro [12–16,55–57].
However, progress in this research area is mainly hindered by the lack of standardized commercial
EPIYA-specific phospho-CagA antibodies, while little information is available about the specificity of
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commercial pan-phosphotyrosine antibodies, such as PY-20, PY-99, and PY-100 [43,44]. Consequently,
after two decades of research, unambiguous conclusions on CagA phosphorylation patterns in clinical
H. pylori isolates during infection are still not available. In this study, we demonstrate the generation
of three pairs of α-phosphotyrosine antibodies recognizing EPIYA-motifs A, B, and C, respectively,
and we have shown that these antibodies display high specificity in recognizing the phosphorylated
as well as the non-phosphorylated EPIYA-sites. We confirmed the specificity of each antibody by
Western blotting against the corresponding phospho-peptides and excluded cross-reactivity with
any non-phospho-peptides. There was only one exception, as antibodies against EPIYA-motif C also
recognized the EPIYA-D site. That cross-reactivity could be expected in view of the similarity in amino
acid sequence between these sites. Subsequently, infection experiments with H. pylori were performed
to study the patterns of CagAPY following delivery into host cells. These data demonstrate for the first
time that each EPIYA-motif can be phosphorylated during infection with both ABC and ABD strains.
Together, these results shed new light on the suitability of such antibodies in H. pylori research and
pinpoint important new avenues for more detailed analyses on CagA phosphorylation-associated
signal transduction events in gastric disease development. For instance, these antibodies may be very
useful to study the subcellular localization of individually phosphorylated CagA protein species in
cells using high resolution fluorescence microscopy, or they could be applied in immunoprecipitation
experiments to identify new host cell binding partners at different phospho-EPIYA motifs.
Remarkably, phosphotyrosine-based signaling is predominant in the domain of higher eukaryotes
with many different known kinases involved, such as Src, Abl, EGFR, c-Met, and others, while
tyrosine kinases such as the class of BY (bacterial tyrosine) kinases are evolutionary distinct from
those in eukaryotes, and some bacteria (including H. pylori) do not encode any known tyrosine
kinase [58–60]. As a consequence, phosphotyrosine-dependent protein–protein interactions have been
mainly studied in mammals, and various commercially available pan-phosphotyrosine antibodies
were initially designed for mammalian proteins [48–51]. These antibodies characteristically recognize
short synthetic phospho-peptides. For example, previous investigations have used microarrays with
20,000 spotted human phospho-peptides to depict the binding capacities of three widely applied
commercial α-pan-phosphotyrosine antibodies, 4G10, PY20, and PY100 [51]. The authors found that
each of these antibodies displays a similar binding capacity for phosphotyrosine, but this depends on
selected neighboring amino acid residues. Favored binding was observed, with phospho-peptides
carrying a leucine at position -1 and proline at position +3 [51]. Interestingly, synthetic phospho-peptides
of the CagA EPIYA-sites were shown to be strongly recognized by six commercial pan-phosphotyrosine
antibodies [43,44]. Using the dotblot approach, we could demonstrate that two of these antibodies (PY20
and PY99) recognized all three phospho-EPIYA peptides A, B, and C with similar and very strong affinity,
confirming that this approach also works for peptides derived from a bacterial effector protein [43,44].
Other commercial pan-phosphotyrosine antibodies mainly recognized phospho-EPIYA peptides A and
C (PY100) or predominantly bound to phospho-EPIYA peptide A, with poor binding to C (PY102) or to
B and C (PY69). In combination, the overall results revealed that four pan-phosphotyrosine antibodies
(PY20, PY69, PY99, and PY100) recognize a broad reservoir of different phospho-EPIYA motifs.
However, in studies of H. pylori infected host cells, most of these commercial pan-phosphotyrosine
antibodies strongly react with host cell proteins of various size ranges as expected, including even
proteins of similar size to CagA (~120–140 kDa), which severely limits their use for studying specific
CagA phosphorylation events in infected cells.
Despite their limitations, pan-phosphotyrosine antibodies have been widely used in early
studies to identify phosphorylated CagA by exploring protein lysates of infected cells separated on
one-dimensional SDS-PAGE gels [34,39–42]. The results obtained in the current study suggest that each
of the CagA EPIYA-sites A, B, C, and D can indeed be phosphorylated during infection. However, the
conclusions of those earlier observations, based on one-dimensional gels, are widely imperfect because
the resulting bands cannot distinguish how many EPIYA-sites are phosphorylated, or which motive is
phosphorylated per single CagA molecule. To overcome this, two-dimensional gel electrophoresis
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was previously employed, which separated different phosphorylated and non-phosphorylated CagA
protein spots [23]. Using this strategy and pan-phosphotyrosine antibody PY99, we had already
demonstrated that CagA from various strains can be concurrently phosphorylated at one or two
EPIYA-motifs per molecule, but never simultaneously at three EPIYA-sites [16,23]. We also determined
that Src kinase only phosphorylated EPIYA-C or EPIYA-D, while Abl kinase phosphorylated EPIYA-A,
-B, -C, and -D motifs in CagA [16]. Our present study identifies a hierarchic phosphorylation model
for CagA starting at EPIYA-C/D, which in our experimental setup was already visible after 45 min of
infection, followed by phosphorylation of EPIYA-A or EPIYA-B, which only became visible at later
time points. These findings led us to propose that a broad collection of differentially phosphorylated
CagA protein molecules are produced in infected host cells, possibly in all possible combinations,
which all may have slightly different functions, and this could explain how CagA may coordinate
signaling to a high number of different host binding partners [16]. To investigate this assumption in
more detail, the EPIYA-specific and phosphorylation-specific CagA antibodies generated in this study
will be most useful. However, from the data we present here it cannot yet be concluded whether single
CagA molecules can be phosphorylated simultaneously at various positions, which we plan to study
in the near future by 2D electrophoresis, as previously described [16]. Moreover, by using Western
blotting it cannot be determined how much of the non-phosphorylated CagA detected with infected
cells had actually been delivered intracellularly, and how much was residual protein still present inside
the adherent bacteria. Lastly, it cannot be excluded that the CagA motifs we detected in host cells with
the non-phospho antibodies were originally translocated and present in the phosphorylated form, to
be subsequently dephosphorylated by host-derived enzymes. It has been described that host protein
tyrosine phosphatases such as SHP1 can display such activity for CagAPY [61]. Thus, it is possible that
the findings during H. pylori infection of AGS cells shown here represent steady state situations that
are the result of changing enzymatic activities in the target cells over time.
The present study focused on the phosphorylation of EPIYA-motifs found in CagA of a diverse
set of H. pylori strains, for which vast differences were detected, but the findings may be relevant to
other bacterial pathogens as well. Tyrosine phosphorylation is a common strategy among bacterial
pathogens, although most do not encode their own tyrosine kinases. Enteropathogenic Escherichia coli,
Citrobacter rodentium, Bartonella henselae, Chlamydia trachomatis, and Anaplasma phagocytophilum all
exhibit a repertoire of remarkable effector proteins (e.g., Tir, BepD, BepE, BepF, Tarp, and AnkA)
carrying EPIYA-like motifs that, similar to CagA, become tyrosine-phosphorylated by host cell kinases
upon delivery into host cells [7,9,62–64]. Subsequently, these phosphorylated effectors have been
shown to bind a selection of cellular interaction partners with Src homology 2 (SH2) domains to
manipulate host cell signaling (for reviews see previous work [9,62,63]). Future investigations will
likely focus on the phosphorylation of EPIYA-motifs in each of these bacterial effector proteins, to
elucidate any resulting signal transduction events in more detail [2,4,17,38,64,65]. For such studies,
the generation of antibodies highly specific for each EPIYA-motif and their phosphorylation state is
necessary, which we have demonstrated here to be feasible. In the future, this would help to better
understand the role of single EPIYA-motifs for bacterial effector protein function and possibly allow
correlations and risk predictions for the occurrence of different microbial diseases.
4. Materials and Methods
4.1. Bioinformatic Analysis of CagA Amino Acid Sequences
The CagA amino acid sequence from H. pylori strain 26695 (accession number WP_000180747)
was retrieved from GenBank and used as a query in BlastP against the H. pylori taxon (Taxid: 210)
at NCBI. Only CagA entries bearing the EPIYA-motif ABC or ABD type were selected for analysis
(Supplementary Table S1). The amino acid sequences were aligned in Muscle [66] and manually edited
in Jalview [67]. The evolutionary history of the CagA amino acid sequences was inferred using the
Neighbor-Joining method [68] with a statistical robustness for the associated taxa of 1000 replicates
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using the bootstrap test [69]. The evolutionary distances were computed using the JTT matrix-based
method, and the rate variation among sites was obtained with a gamma distribution (shape parameter
= 2) [70]. The evolutionary analyses were conducted in MEGA7 [71] and the final tree was visualized
in Itol [72].
4.2. H. pylori Strains and Culturing Conditions
The wild-type H. pylori strains Gam94-24, N6, P1, 26695, PMSS1, 7.13, TN2-GF4, and Sat464
were typical type-I isolates expressing CagA (Supplementary Table S1). The bacteria were grown on
horse serum gonococcal (GC) agar plates containing vancomycin (10 µg/mL), nystatin (1 µg/mL), and
trimethoprim (5µg/mL), and in the case of mutants kanamycin (8µg/mL), as described previously [73,74].
Mutagenesis of the cagL gene was performed by insertion of a kanamycin resistance gene cassette as
described [75]. All antibiotics were obtained from Sigma-Aldrich. Bacteria were grown at 37 ◦C for
2 days in an anaerobic jar containing a Campygen gas mix of 5% O2, 10% CO2, and 85% N2 (Oxoid,
Wesel, Germany) [76,77].
4.3. Production of Phospho-and Non-Phospho-Specific EPIYA Antibodies
The following peptide sequences were synthesized by Jerini (Berlin, Germany): C-STEPIYAKVNK
(EPIYA-A), C-STEPI(pY)AKVNK (phospho-EPIYA-A), C-PEEPIYTQVAK (EPIYA-B), C-PEEPI(pY)TQVAK
(phospho-EPIYA-B), C-SPEPIYATIDD (EPIYA-C), and C-SPEPI(pY)ATIDD (phospho-EPIYA-C).
The peptides C-SPEPIYATIDF (EPIYA-D) and C-SPEPI(pY)ATIDF (phospho-EPIYA-D) were synthesized
for use of as controls. Each of these EPIYA peptides was purified by High Performance Liquid
Chromatography (HPLC) and their purity was approved by mass spectrometry analysis (Jerini, Berlin,
Germany). All peptides were synthesized with an additional amino-terminal cysteine residue to which
Limulus polyphemus haemocyanin (LPH) carrier protein was conjugated (Biogenes, Berlin, Germany).
Two rabbits were immunized with each conjugated peptide according to a standard protocol by
Biogenes using an immunization schedule summarized in Table 1. The resulting antisera were used
to select phospho-specific antibodies by affinity-removal of the corresponding non-phospho-peptide
of each EPIYA-motif bound to a column. Conversely, the obtained non-phospho antibodies were
affinity-purified using columns against the corresponding phospho-peptide. These antibodies were
prepared on a customer basis and purified by Biogenes.
Table 1. Time scheme of rabbit immunization.
Day Step
0 Peptide synthesis and LPH coupling
0 Collection of pre-immune serum
0 First immunization of 2 rabbits
7 First boost
14 Second boost
28 Third boost
42 Bleeding, fourth boost
56 Fifth boost
70 Sixth boost
77 Bleeding
105 Final bleeding, serum IgG purification
4.4. Dotblot Analysis
Dotblots were prepared by spotting 20 µg of each peptide in 1 mL of transfer buffer (192 mM
Glycine; 20 mM Tris-HCl, pH 8.4; 0.1% SDS; 20% Methanol) onto Immobilon-P membrane (Millipore,
Darmstadt, Germany) using the BioDot apparatus (BioRad, Munich, Germany) [78,79]. The resulting
dotblots were dried at 37 ◦C and subjected to antibody detection by Western blots, as described below.
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4.5. Host Cell Culture, Infection Assays, and Elongation Phenotype Quantitation
The human gastric adenocarcinoma cell line AGS (ATCC CRL-1739™) was cultured on 6-well
plates in RPMI1640 medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum
(Invitrogen) and a penicillin/streptomycin cocktail (Sigma-Aldrich, Taufkirchen, Germany). The cells
were grown in 5% (v/v) CO2 at 37 ◦C [80,81]. When the cells reached about 75% confluency, they
were washed two times with Phosphate Buffered Saline (PBS) and fresh RPMI1640 medium without
antibiotics was added [82,83]. Cells were serum-deprived overnight and infected with H. pylori at a
multiplicity of infection (MOI) of 50 for 6 h. After infection, the cells were harvested in ice-cold PBS
containing 1 mmol/l Na3VO4 (Sigma-Aldrich). Using an Olympus IX50 phase contrast microscope,
the elongated AGS cells were quantitated in 10 different 0.25-mm2 fields per experiment [84,85].
All experiments were done in triplicate.
4.6. SDS-PAGE and Western Blotting
Infected AGS cells were washed twice with PBS to remove unbound bacteria, and then the cells
were harvested with attached bacteria, pelleted, and resuspended in equal amounts of 2× SDS-PAGE
buffer. Proteins were boiled for 5 min and then subjected to SDS-PAGE. The proteins were resolved
in 6% polyacrylamide gels and blotted onto Immobilon-P membranes (Millipore). Membranes were
blocked in Tris-buffered saline with Tween20 (TBST) buffer with 3% bovine serum albumin (BSA) or 5%
skim milk for 1 h at room temperature followed by incubation with the generated α-phosphotyrosine
and non-phospho CagA antibodies [86,87]. As controls, we used a rabbit polyclonal α-CagA antibody
(Austral Biologicals, San Ramon, CA, USA) and the mouse monoclonal pan-phosphotyrosine antibody
PY-99 (Santa Cruz, Dallas, TX, USA) according to the instructions by the manufacturers. Phosphorylated
and non-phosphorylated CagA proteins were detected using horseradish peroxidase-conjugated
anti-rabbit or anti-mouse polyvalent goat immunoglobulin secondary antibodies visualized by the
Amersham enhanced chemiluminescence (ECL) Prime Western blot kit (GE Healthcare, Munich,
Germany), as described previously [88,89].
4.7. Statistical Analysis
The intensities of the Western blot signals, derived from three independent experiments, were
measured and quantitated densitometrically by the Image Lab™ software (Bio-Rad). For each
α-phosphotyrosine and α-non-phospho CagA/EPIYA Western blot, shown in Figures 5 and 6C,D,
the strongest band on the gels was set to 100% and the relative intensities of every single band on
the respective blot were calculated (Supplementary Figure S3 and Figure 6E,F). The error bars for
quantifying relative band intensities in Supplementary Figure S3 and number of elongated cells shown
in Figure 4 represent the standard error of the mean (SEM) calculated with Excel software.
5. Conclusions
All commercially available pan-phosphotyrosine antibodies were originally produced to detect a
wide array of phosphotyrosines in multiple mammalian proteins, but were not optimized for usage
in bacterial effector proteins. Here we generated 11-mer phospho- and non-phospho-peptides
from the EPIYA-motifs A, B, and C of H. pylori CagA, and produced three phospho-specific
and three non-phospho-specific polyclonal antibodies in rabbits. We demonstrated that these
antibodies specifically detect the corresponding phosphorylated and non-phosphorylated EPIYA-motifs.
Interestingly, the EPIYA-C antibodies also recognized the closely related East-Asian motif EPIYA-D
in vitro. Furthermore, we showed that each EPIYA-motif can be efficiently phosphorylated during
infection with H. pylori ABC and ABD strains in vivo. Together, we present here the first complete set
of phospho-specific antibodies for a bacterial effector protein, which are new beneficial tools to collect
important data for cataloguing CagA phosphorylation events, disease development in the human
stomach and gastric cancer signal transduction.
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